Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 8/20 | 0.42 |
| ▸ | UBE2M | P61081 | 3/20 | 0.40 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2749695 | 1.00 | FYN (0.45) | FYNCDK1CDK2MKNK1MKNK2 | |
| SCHEMBL2749334 | 0.90 | FYN (0.47) | FYNCDK1CDK2MKNK1MKNK2 | |
| SCHEMBL2748832 | 0.90 | HSD17B10 (0.47) | FYNCDK1CDK2MKNK1MKNK2 | |
| SCHEMBL2748836 | 0.90 | HSD17B10 (0.47) | FYNCDK1CDK2MKNK1MKNK2 | |
| SCHEMBL2749333 | 0.90 | FYN (0.47) | FYNCDK1CDK2MKNK1MKNK2 | |
| SCHEMBL2749700 | 0.86 | ATR (0.52) | FYNLRRK2ATRUBE2MDCUN1D1 | |
| SCHEMBL2750485 | 0.85 | FYN (0.53) | FYNCDK1CDK2MKNK1MKNK2 | |
| SCHEMBL2749343 | 0.85 | FYN (0.62) | FYNLRRK2ATRUBE2MDCUN1D1 | |
| SCHEMBL2750571 | 0.85 | ATR (0.51) | FYNLRRK2ATRUBE2MDCUN1D1 | |
| SCHEMBL2747927 | 0.85 | ATR (0.55) | FYNLRRK2ATRUBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178668-B2 | 2-aminopyridine kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2265270-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009099982-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | FYN 75/4885CDK1 298/4885CDK2 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.